43 completed, 5 terminated, 5 unknown, 3 withdrawn. 58 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 58 | Completed 43, Terminated 5, Unknown 5, Withdrawn 3, Active not recruiting 1, Recruiting 1 |
Follow Timolol: new trials by email Literature Review of Timolol trials Research Report on Timolol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Timolol Maleate 0.25% Ophthalmic Solution - Open Angle Glaucoma (OAG), Glaucoma | Phase 4 | Recruiting | Brett King | 13 | 2026-10-01 | 2026-10-28 |
| How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure? dorzolamide/timolol - Glaucoma, Open-Angle, Glaucoma; Drugs | Phase 4 | Terminated | CT Glaucoma Associates | 36 | 2024-04-22 | 2024-08-23 |
| Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas Propranolol three times a day, Propranolol twice a day, Timolol - Infantile Hemangioma | Phase 4 | Terminated | The University of Texas Health Science Center, Houston | 52 | 2022-06-23 | 2026-03-13 |
| Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensive BRIDIN-plus Eye drops, Combigan Eye drops - Glaucoma, Ocular Hypertensive | Phase 4 | Completed | CHA University | 60 | 2021-10-08 | 2025-03-26 |
| Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma Triple combination formula, Bimatoprost .03% sterile ophthalmic solution - Glaucoma, Quality of Life (QOL) | Phase 4 | Active not recruiting | Federal University of São Paulo | 40 | 2021-03-01 | 2025-01-07 |
| Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution - Glaucoma, OHT - Ocular Hypertension | Phase 4 | Completed | Ohio State University | 59 | 2020-11-23 | 2026-03-04 |
| 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration. tafluprost/timolol - Glaucoma, Open-Angle, Ocular Hypertension | Phase 4 | Unknown | Fondazione G.B. Bietti, IRCCS | 43 | 2020-06-04 | 2022-03-29 |
| Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma oral propranolol, Oral Captopril, intralesional propranolol injection - Infantile Hemangioma | Phase 4 | Unknown | Ain Shams University | 100 | 2019-10-01 | 2020-02-28 |
| Efficacy and Safety of Latanoprost/Timolol for Primary Open Angle Glaucoma Latanoprost/Timolol - Primary Open Angle Glaucoma | Phase 4 | Unknown | Universiti Kebangsaan Malaysia Medical Centre | 40 | 2019-01-02 | 2019-09-23 |
| Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study Timolol Maleate, Brimonidine Tartrate - Glaucoma; Drugs, Normal Tension Glaucoma | Phase 4 | Completed | Wills Eye | 35 | 2017-07-10 | 2020-12-31 |
| Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV® Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution - Open-angle Glaucoma, Ocular Hypertension | Phase 4 | Terminated | Alcon Research | 173 | 2016-06-24 | 2019-05-29 |
| 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy tafluprost, tafluprost and dorzolamide/timolol - Glaucoma, Ocular Surface Disease | Phase 4 | Completed | Aristotle University Of Thessaloniki | 43 | 2015-03-01 | 2020-12-17 |
| Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, Subject's habitual PGA monotherapy - Open-Angle Glaucoma, Ocular Hypertension | Phase 4 | Completed | Alcon, a Novartis Company | 218 | 2014-12-01 | 2016-12-08 |
| The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Prostaglandin Analog, Timolol - Thyroid Eye Disease, Ocular Hypertension | Phase 4 | Withdrawn | Stanford University | 2014-06-01 | 2018-05-15 | |
| Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension bimatoprost 0.01%, travoprost 0.004%, timolol 0.5% - Glaucoma, Ocular Hypertension | Phase 4 | Completed | Allergan | 100 | 2014-05-01 | 2016-01-14 |
| Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma Brimonidine Tartrate, Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops, Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension - Glaucoma, Open-Angle | Phase 4 | Completed | Afyon Kocatepe University Hospital | 96 | 2014-01-01 | 2019-05-29 |
| Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure Beta-blocker monotherapy, Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution - Open Angle Glaucoma, Ocular Hypertension | Phase 4 | Completed | Alcon Research | 157 | 2013-12-01 | 2016-08-08 |
| Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension, Timolol Maleate 0.5% - Open-Angle Glaucoma, Ocular Hypertension | Phase 4 | Completed | Alcon Research | 89 | 2013-10-01 | 2015-04-13 |
| An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension bimatoprost 0.01%, travatan 0.004%, timolol 0.5% - Glaucoma, Ocular Hypertension | Phase 4 | Completed | Allergan | 93 | 2013-06-01 | 2015-11-30 |
| Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav) - Glaucoma, Ocular Hypertension | Phase 4 | Withdrawn | Alcon Research | 2013-02-01 | 2013-02-07 |
Showing 20 of 58. Sign in to see all of them.
Glaucoma (33) · Glaucoma, Open-Angle (31) · Ocular Hypertension (30) · Eye Diseases (3) · Hemangioma, Capillary (2) · Low Tension Glaucoma (2) · Exfoliation Syndrome (1) · Glaucoma, Angle-Closure (1) · Graves Disease (1) · Graves Ophthalmopathy (1) · Patient Compliance (1)
Alcon Research (16) · Allergan (10) · Aristotle University Of Thessaloniki (4) · Pharmaceutical Research Network (3) · Bp Consulting, Inc (2) · Afyon Kocatepe University Hospital (1) · Ain Shams University (1) · Alcon, a Novartis Company (1) · Brett King (1) · CHA University (1) · CT Glaucoma Associates (1) · Credit Valley EyeCare (1) · Federal University of São Paulo (1) · Fondazione G.B. Bietti, IRCCS (1) · Glaukos Corporation (1)
United States (23) · Canada (8) · Greece (4) · Germany (3) · Italy (3) · Spain (3) · Portugal (2) · South Korea (2) · Armenia (1) · Austria (1) · Brazil (1) · Egypt (1) · France (1) · Japan (1) · Malaysia (1)
William C. Stewart, MD (4) · Abayomi Ogundele, PharmD (2) · Anastasios G Konstas, MD, PhD (2) · Elizabeth D. Sharpe, MD (2) · Severine Durier, Pharm.D (2) · Amandeep S Rai, MD (1) · Anastasios GP Konstas, MD, PhD (1) · Anastasios Konstas, MD, phD (1) · Andrea L. Kossler, M.D. (1) · Anna Grau (1) · Barbara Cvenkel, MD (1) · Carolina Gracitelli, Affiliate Professsor (1) · Cindy M. Hutnik, BSc, PhD, MD (1)
PMID 19476406, PMID 12614754, PMID 14509472, PMID 16303952, PMID 17102003, PMID 20505839, PMID 21773673, PMID 21960068, PMID 22458918, PMID 24855336, PMID 27913991, PMID 28239491, PMID 40341017, PMID 8562550
2009 (1), 2016 (1), R01EY022124 (1)